Bristol-Myers Squibb Company

Bristol-Myers Squibb Company
430 E. 29th Street, 14th Floor,
New York, NY 10016
Phone: 1-800-332-2056Website: https://www.bms.com/Careers: www.bms.com/careers/Pages/home.aspxPatient Assistance Program: www.bms.com/products/Pages/programs.aspx

Latest news

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
22 April 2025
U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
17 April 2025
Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial
14 April 2025
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
11 April 2025
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer
8 April 2025
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
27 December 2024
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
3 October 2024
FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
27 September 2024
FDA Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
13 June 2024
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
30 May 2024

Drugs Associated with Bristol-Myers Squibb Company

Bristol-Myers Squibb Company manufactures, markets and/or distributes more than 35 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Brand/Generic Name	Reviews	Rating
Abecma Generic name: idecabtagene vicleucel Drug class: miscellaneous antineoplastics
Abraxane Generic name: paclitaxel protein-bound Drug class: mitotic inhibitors	5 reviews	6.2 / 10
Augtyro Generic name: repotrectinib Drug class: multikinase inhibitors
Azactam Generic name: aztreonam Drug class: monobactams
Baraclude Generic name: entecavir Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)	1 review	10 / 10
Breyanzi Generic name: lisocabtagene maraleucel Drug class: miscellaneous antineoplastics
Camzyos Generic name: mavacamten Drug class: miscellaneous cardiovascular agents	8 reviews	8.8 / 10
Cobenfy Generic name: trospium/xanomeline Drug class: psychotherapeutic combinations	2 reviews	6.0 / 10
Droxia Generic name: hydroxyurea Drug class: antimetabolites
Eliquis Generic name: apixaban Drug class: factor Xa inhibitors	213 reviews	5.3 / 10
Empliciti Generic name: elotuzumab Drug class: miscellaneous antineoplastics
Evotaz Generic name: atazanavir/cobicistat Drug class: antiviral combinations
Hydrea Generic name: hydroxyurea Drug class: antimetabolites	8 reviews	7.2 / 10
Idhifa Generic name: enasidenib Drug class: miscellaneous antineoplastics
Inrebic Generic name: fedratinib Drug class: multikinase inhibitors
Istodax Generic name: romidepsin Drug class: histone deacetylase inhibitors	1 review	1.0 / 10
Kenalog-10 Generic name: triamcinolone Drug class: glucocorticoids	21 reviews	8.0 / 10
Kenalog-40 Generic name: triamcinolone Drug class: glucocorticoids	111 reviews	6.4 / 10
Nulojix Generic name: belatacept Drug class: selective immunosuppressants	1 review	10 / 10
Onureg Generic name: azacitidine Drug class: miscellaneous antineoplastics
Opdivo Generic name: nivolumab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)	82 reviews	5.5 / 10
Opdivo Qvantig Generic name: hyaluronidase/nivolumab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Opdualag Generic name: nivolumab/relatlimab Drug class: antineoplastic combinations
Orencia Generic name: abatacept Drug class: antirheumatics, selective immunosuppressants	66 reviews	6.0 / 10
Pomalyst Generic name: pomalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants	3 reviews	10 / 10
Reblozyl Generic name: luspatercept Drug class: miscellaneous erythropoiesis agents	5 reviews	9.6 / 10
Revlimid Generic name: lenalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants	23 reviews	7.0 / 10
Reyataz Generic name: atazanavir Drug class: protease inhibitors	4 reviews	8.8 / 10
Sotyktu Generic name: deucravacitinib Drug class: selective immunosuppressants	12 reviews	6.3 / 10
Sprycel Generic name: dasatinib Drug class: BCR-ABL tyrosine kinase inhibitors	21 reviews	7.5 / 10
Sustiva Generic name: efavirenz Drug class: NNRTIs	6 reviews	5.2 / 10
Thalomid Generic name: thalidomide Drug class: leprostatics, miscellaneous antineoplastics, other immunosuppressants
Vidaza Generic name: azacitidine Drug class: miscellaneous antineoplastics	13 reviews	5.5 / 10
Yervoy Generic name: ipilimumab Drug class: anti-CTLA-4 monoclonal antibodies	2 reviews	9.5 / 10
Zeposia Generic name: ozanimod Drug class: selective immunosuppressants	6 reviews	8.3 / 10
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).